Browsing tag:

gastroesophageal reflux disease


Famotidine, CAS number 76824-35-6, is an effective, tolerable and well- studied treatment for patients with both peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Schwarz Pharma holds the patent for this cogent medication, as the brand name Fluxid, with an expiration due on April 9, 2018.  As an H2 receptor, or histamine blocker receptor,[…]

Read More

Histamine-2 blockers are commonly prescribed for patients with gastroesophageal reflux disease, also known as GERD. Famotidine is an effectual treatment and histamine-2 blocker used to treat many of these patients, also known by the household names Pepcid, Pepcid AC and Mylanta. With the patent for Pepcid AC geltabs expiring on December 29. 2015, researchers are[…]

Read More

Patients suffering from Gastroesophageal Reflux Disease (GERD), benefit greatly from esomeprazole. Also known as Prilosec I.V. in the United States, AstraZeneca will see their patent of this breakout drug expire in May of 2014. The International Foundation for Functional Gastrointestinal Disorders recently reported that health professionals from the American Gastroenterological Association estimate that 33 percent[…]

Read More

In developed nations, between 20-40 percent of adults experience heartburn on a regular basis. Heartburn is characterized by a burning sensation that rises from the stomach towards the chest and neck. It has often been mistaken as angina, a symptom of heart attack. Heartburn is the primary symptom of gastroesophageal reflux disease (GERD). When left[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service